Aclaris Therapeutics (NASDAQ:ACRS) Releases Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Aclaris Therapeutics (NASDAQ:ACRSGet Rating) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.10, Briefing.com reports. Aclaris Therapeutics had a negative return on equity of 47.82% and a negative net margin of 1,343.96%. The company had revenue of $1.45 million for the quarter, compared to the consensus estimate of $1.67 million. The company’s revenue for the quarter was down 18.2% on a year-over-year basis.

ACRS stock traded up $0.07 during trading on Thursday, reaching $10.23. 31,299 shares of the company were exchanged, compared to its average volume of 497,592. Aclaris Therapeutics has a 52-week low of $9.26 and a 52-week high of $24.00. The company has a market cap of $626.84 million, a P/E ratio of -6.17 and a beta of 0.67. The stock’s 50 day moving average price is $15.40 and its 200 day moving average price is $14.13.

In other Aclaris Therapeutics news, insider Joseph Monahan sold 27,165 shares of the firm’s stock in a transaction dated Thursday, March 10th. The stock was sold at an average price of $15.71, for a total value of $426,762.15. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Neal Walker sold 56,303 shares of Aclaris Therapeutics stock in a transaction dated Friday, March 11th. The shares were sold at an average price of $15.91, for a total value of $895,780.73. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 171,291 shares of company stock valued at $2,694,941. Insiders own 8.20% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in ACRS. BlackRock Inc. grew its stake in shares of Aclaris Therapeutics by 7.7% during the fourth quarter. BlackRock Inc. now owns 4,078,875 shares of the biotechnology company’s stock valued at $59,307,000 after acquiring an additional 290,458 shares in the last quarter. Barclays PLC boosted its stake in shares of Aclaris Therapeutics by 100.4% during the 4th quarter. Barclays PLC now owns 100,518 shares of the biotechnology company’s stock valued at $1,461,000 after buying an additional 50,349 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Aclaris Therapeutics by 34.8% during the third quarter. Bank of New York Mellon Corp now owns 182,245 shares of the biotechnology company’s stock worth $3,281,000 after buying an additional 47,003 shares in the last quarter. Bank of America Corp DE raised its stake in Aclaris Therapeutics by 173.8% during the fourth quarter. Bank of America Corp DE now owns 60,658 shares of the biotechnology company’s stock valued at $882,000 after buying an additional 38,506 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its position in shares of Aclaris Therapeutics by 11.1% during the 4th quarter. Nuveen Asset Management LLC now owns 302,156 shares of the biotechnology company’s stock valued at $4,393,000 after acquiring an additional 30,066 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Several brokerages recently weighed in on ACRS. Zacks Investment Research raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. Cantor Fitzgerald restated an “overweight” rating on shares of Aclaris Therapeutics in a report on Friday, February 25th. Finally, StockNews.com assumed coverage on shares of Aclaris Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $30.50.

Aclaris Therapeutics Company Profile (Get Rating)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.

Featured Articles

Earnings History for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.